ZSCAN9 Knockout cell line (LN-229)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZSCAN9 (zinc finger and SCAN domain containing 9) encodes a zinc finger protein with sequence-specific double-stranded DNA-binding activity and a predicted role in regulation of RNA polymerase II-dependent transcription. ZSCAN9 is predicted to localize to the nucleus, consistent with a potential role in transcriptional regulation. It is relevant to studies of zinc finger proteins, DNA-dependent gene regulation, nuclear transcriptional control, and regulation of cellular gene expression.

Established in 1979, LN-229 is a widely recognized and standard human glioblastoma cell line. The line was isolated from cells taken from a patient presenting with a malignant right frontal parieto-occipital glioblastoma (PubMed: 10416987). LN-229 cells adhere stably in culture, displaying an epithelial-like morphology, and are extensively utilized to study apoptotic pathways, cellular autophagy, and tumor suppressor gene interactions within neuro-oncology. Consequently, LN-229 serves as a premier and robust in vitro platform utilized globally for investigating glioblastoma multiforme (GBM) progression mechanisms, blood-brain barrier penetrating candidate drug screenings, and the evaluation of targeted therapeutic modalities.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.